AXSM: AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials
Robust commercial growth is driven by AUVELITY's expanded sales force and new Alzheimer's agitation indication, with strong Medicare coverage and early positive feedback. The late-stage pipeline includes multiple phase III trials, and financials show a strong cash position and improving gross-to-ne…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.